Clinical trials: Pneumococcal Vaccine
Vaccines, Pneumococcal
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations…
- Trial name
- NCT00366899
- Testing
- 13-valent pneumococcal conjugate vaccine, 7 valent pneumococcal conjugate vaccine
- Where
- 13 sites in Italy
- Volunteers
- 605 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japan, Korea, and Taiwan
- Trial name
- NCT04875533
- Testing
- 20vPnC, Saline, 13vPnC
- Where
- 28 sites in Japan, South Korea and 1 more
- Volunteers
- 1,425 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Meningococcal
Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
The purpose of this study is to compare the immediate and long term (up to 5 years) immunogenicity and safety of GSK Biologicals' MenACWY-TT vaccine when given as a single dose or as 2 doses to toddlers aged 12 to 14 months.
- Trial name
- NCT01939158
- Testing
- Meningococcal vaccine GSK134612, Prevenar 13™
- Where
- 51 sites in Australia, Canada and 4 more
- Volunteers
- 803 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
The purpose of this study is to evaluate the safety and immunogenicity of sequential administration of Prevnar 13™ and Pneumovax™ 23 in healthy participants 50 years of age and older.
- Trial name
- NCT02225587
- Testing
- Prevnar 13™, Pneumovax™ 23
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Relapsing Forms of Multiple Sclerosis
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012)…
- Trial name
- NCT02097849
- Testing
- dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 14 sites in United States
- Volunteers
- 71 people
- Sponsor
- Biogen
Pneumococcal Disease
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Trial name
- NCT04382326
- Testing
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Where
- 110 sites in United States, Puerto Rico
- Volunteers
- 1,997 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal, Streptococcus Pneumoniae Vaccines
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to 48-50 months post booster vaccination, to assess long-term antibody persistence in children at around 30, 42 and 66 months of age, who…
- Trial name
- NCT00624819
- Testing
- GSK1024805A, Prevenar, Infanrix hexa
- Where
- 6 sites in Poland
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India
This study is to describe the safety and immunogenicity of 13vPnC in Indian adults 50 to 65 years of age and in Indian children 6 to 17 years of age.
- Trial name
- NCT02034877
- Testing
- 13-valent Pneumococcal conjugate vaccine, Blood sample collection
- Where
- 16 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease
Post Market Surveillance to Observe Safety of Prevenar13™ in Adults
The purpose of this study is to assess safety profile of Prevenar 13™ when used among Korean adults in the routine clinical setting, as required for any new drug approved by Korea Food and Drug Administration (KFDA).
- Trial name
- NCT01834222
- Testing
- Non-intervention
- Where
- 27 sites in South Korea
- Volunteers
- 659 people
- Sponsor
- Pfizer
Haemophilus Influenzae Type b, Neisseria Meningitidis
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine
This study is evaluating the safety and immunogenicity of GSK Biologicals' Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, each administered at 2, 4, and 6 months of age, and compared to…
- Trial name
- NCT00129129
- Testing
- GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix
- Where
- 27 sites in United States
- Volunteers
- 756 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Pneumonia, Influenza
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza…
- Trial name
- NCT02592486
- Testing
- Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe®
- Where
- Japan
- Volunteers
- 162 people
- Sponsor
- Kameda Medical Center
Nasopharyngeal Carriage of S. Pneumoniae
Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
The specific aim is to evaluate the impact of PCV13 as administered in the pediatric primary care clinic at Boston medical center on the serotype specific carriage of Streptococcus pneumoniae in children < 5.
- Trial name
- NCT01109108
- Where
- United States
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Healthy Subjects, Pneumococcal Infections
Study Evaluating Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants. This is the first study with this vaccine in infants.
- Trial name
- NCT00205803
- Testing
- 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines, Pneumococcal Conjugate Vaccine
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.
- Trial name
- NCT00574795
- Testing
- 13vPnC
- Where
- 24 sites in Japan
- Volunteers
- 193 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Vaccines
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Phase 2 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)
- Trial name
- NCT06077656
- Testing
- IVT PCV-25 Formulation A, IVT PCV-25 Formulation B, IVT PCV-25 Formulation C
- Where
- 4 sites in Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Inventprise Inc.
Healthy Children After Vaccination
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
This study is planned to monitor the local and/or systemic reactions and compatibility of PCV-7 with routine vaccines in the Russian National immunization schedule.
- Trial name
- NCT01207583
- Testing
- Non-interventional observational study
- Where
- 4 sites in Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Vaccines
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
This study will compare the immune responses of the infants who have been given 13vPnC in the mutidose vial formulation to the immune reponses of the infants who have been given 13vPnC in the single-dose syringe formulation.
- Trial name
- NCT01964716
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 2 sites in The Gambia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment
The aim of the current study is to determine whether ibuprofen, given as immediate or delayed prophylactic antipyretic treatment in a standardized manner, significantly impacts the immune response in children receiving primary…
- Trial name
- NCT01235949
- Testing
- GSK1024850A (SynflorixTM), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 23 sites in Romania
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccines, Pneumococcal
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of 13-valent pneumococcal vaccine in healthy infants given with routine pediatric vaccinations in Mexico.
- Trial name
- NCT00708682
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- 9 sites in Mexico
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study…
- Trial name
- NCT00500266
- Testing
- 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- Where
- 59 sites in United States, Germany and 1 more
- Volunteers
- 1,053 people, healthy volunteers welcome
- Sponsor
- Pfizer